Myriad Genetics accelerates Alzheimer's drug trial process

01/13/2005 | Forbes

The company says it is starting a Phase III trial before the end of its mid-stage trial for Flurizan to evaluate the drug's ability to slow cognitive and behavioral changes seen in Alzheimer's patients. One analyst said the accelerated testing process could lead to an FDA filing in late 2006 or early 2007.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC